Literature DB >> 20408859

Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment.

V H Barbai1, E Ujhelyi, J Szlávik, I Vietorisz, L Varga, E Fey, G Füst, D Bánhegyi.   

Abstract

Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly active anti-retroviral therapy (HAART) treatment, with undetectable viral load, but low CD4+ cell count (<300/microl), have been treated with 3.6 M IU Proleukine administered twice daily by subcutaneous injection over 5 days. C-reactive protein (CRP), D-dimer, C3, C9, C1-inh and alpha-2HS glycoprotein levels were measured immediately before IL-2 administration, as well as on day 5 and 2-3 weeks thereafter. After IL-2 administration, both mean D-dimer and CRP levels increased significantly (P<0.001), but returned (P<0.001) to baseline within the subsequent 2-3 weeks. Alpha-2HS glycoprotein decreased immediately after IL-2 administration. No significant differences were detected in the levels of C3, C9 and C1-inh. A significant, positive correlation (r=0.5178, P=0.0008) was ascertained between the changes of CRP level, measured immediately before as well as 5 days after IL-2 administration, and changes in CD4 T cell counts measured 2-3 weeks before and after treatment, respectively. IL-2 administration induces rapid elevation of two major APPs (CRP, D-dimer). The positive correlation observed between the changes of CRP levels and CD4+ cell counts after IL-2 administration may indicate that the abrupt, but transitory overproduction of CRP might contribute to the CD4+ cell count-increasing effect of the drug and/ or may be associated with serious side effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20408859      PMCID: PMC2940158          DOI: 10.1111/j.1365-2249.2010.04145.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  D-dimer levels are markedly raised in HIV-related thrombotic thrombocytopenic purpura.

Authors:  Karen Gunther; Bernice Dhlamini
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

2.  Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy.

Authors:  K M Heaton; G Ju; E A Grimm
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

3.  Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels.

Authors:  Brian O Porter; Jean Shen; Joseph A Kovacs; Richard T Davey; Catherine Rehm; Jay Lozier; Gyorgy Csako; Khanh Nghiem; Rene Costello; Henry Clifford Lane; Irini Sereti
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

4.  AIDS: no association with the genetic systems GC (D-binding protein), ORM (orosomucoid = alpha-1-acid glycoprotein), and A2HS (alpha-2-HS-glycoprotein).

Authors:  H Cleve; S Weidinger; L G Gürtler; F Deinhardt
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 5.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

6.  Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).

Authors:  Christine Durier; Catherine Capitant; Anne-Sophie Lascaux; Cécile Goujard; Eric Oksenhendler; Isabelle Poizot-Martin; Jean-Paul Viard; Laurence Weiss; Emmanuelle Netzer; Jean-François Delfraissy; Jean-Pierre Aboulker; Yves Lévy
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

7.  Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).

Authors:  Mary A Vogler; Hedy Teppler; Rebecca Gelman; Fred Valentine; Michael M Lederman; Roger J Pomerantz; Richard B Pollard; Deborah Weng Cherng; Charles J Gonzalez; Kathleen E Squires; Ian Frank; Donna Mildvan; Laura F Mahon; Barbara Schock
Journal:  J Acquir Immune Defic Syndr       Date:  2004-05-01       Impact factor: 3.731

8.  Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.

Authors:  D J Deehan; S D Heys; W Simpson; R Herriot; J Broom; O Eremin
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

9.  CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.

Authors:  Roberto C Arduino; Esteban C Nannini; Maria Rodriguez-Barradas; Shannon Schrader; Marcelo Losso; Kiat Ruxrungtham; Maria C Allende; Sean Emery; Lisa Fosdick; James Neaton; Jorge A Tavel; Richard T Davey; H Clifford Lane
Journal:  Clin Infect Dis       Date:  2004-06-14       Impact factor: 9.079

10.  A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.

Authors:  A C Ogilvie; J W Baars; A J Eerenberg; C E Hack; H M Pinedo; L G Thijs; J Wagstaff
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more
  4 in total

Review 1.  Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development.

Authors:  Sheila M Keating; Evan S Jacobs; Philip J Norris
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

2.  Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.

Authors:  Norman Markowitz; Gustavo Lopardo; Deborah Wentworth; Daniela Gey; Abdel Babiker; Lawrence Fox; Jorge Tavel
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

Review 3.  The Use of Recombinant Feline Interferon Omega Therapy as an Immune-Modulator in Cats Naturally Infected with Feline Immunodeficiency Virus: New Perspectives.

Authors:  Rodolfo Oliveira Leal; Solange Gil
Journal:  Vet Sci       Date:  2016-10-27

4.  Monitoring acute phase proteins in retrovirus infected cats undergoing feline interferon-ω therapy.

Authors:  R O Leal; S Gil; N Sepúlveda; D McGahie; A Duarte; M M R E Niza; L Tavares
Journal:  J Small Anim Pract       Date:  2013-11-27       Impact factor: 1.522

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.